Usually lawsuits meant for company's share holders who made losses due to company's wrongful act. In case of Orexigen they have worked in the interest of shares holders by registering patent,on CVOT outcome. Share holders investment appreciated (not lost) due to increase in share price...........So I don't understand, Lawsuits will be trying to prove...?
Yes ! losses are made by the Short sellers, however such act do not constitute any lawsuits, also do not cover compensations to the short sellers. By registering a patent company has done nothing wrong.
EU deal by this week end we might get $15-20 Open ...Not less than $3 Billion in Total payments as Milestone payments for EU and rest of the world.
200 Million Total Shares issued - 131Million is still outstanding - 7 million SOLD ...Long way to go for this fraudster.
7 Million Shares SOLD, they have more than 100Million shares to dump in the market, make their fortune money and disappear.
Tom Cannell has joined as Chief Commercial Officer. As the Company prepares for global commercialization of Contrave® /Mysimba™ (naltrexone HCl / bupropion HCl extended release), Cannell will lead all aspects of Orexigen's global commercial strategy, assuming responsibilities previously held by Mark Booth.
Does Takeda remain interested for Ex-US and FDC opportunities?
Yes. The following is what Mr. Mike Narachi, CEO of Orexigen discussed during RBC Healthcare Conference just 2 weeks ago:
Simos Simeonidis, RBC Capital analyst: …...Can you walk us through the different lifecycle management opportunities for Contrave?
Mike Narachi, CEO-Orexigen: Ya, again I want to talk on a global basis because just I don't want to speak on behalf of our partner Takeda who is evaluating opportunities and needs to make decisions on what to invest in and (what) not to invest in, ….
All brokers are advised to close their short position before breaking PR....calculated game ...Just like ISIS Pharmaceuticals last year ...all lawsuits grabbed most shares below $10 and then ...all the way to $60..$80
All brokers are advised to close their short position!! Today 11.00am was cutoff time.
Obesity Drug Market Will Increase More Than Six-Fold over the Next Decade, Increasing to $2.6 Billion in 2020 in the U
Market Growth Will Be Driven By the Rapid Uptake of Novel Emerging Agents and the High Prevalence of Obesity, According to Findings from Decision Resources
BURLINGTON, Mass.--(BUSINESS WIRE)-- Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that the obesity drug market will increase more than six-fold over the next decade, increasing from $420 million in 2010 to $2.6 billion in 2020 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. Market growth will be driven by the rapid uptake of novel emerging agents and the high prevalence of obesity.